Navigation Links
Pharmaceuticals: Global Industry Guide
Date:1/8/2013

NEW YORK, Jan. 8, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceuticals: Global Industry Guide

http://www.reportlinker.com/p0191852/Pharmaceuticals-Global-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

Pharmaceuticals: Global Industry Guide is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.

Scope of the Report * Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Covers the Global, European and Asia-Pacific markets as well as individual chapters on 5 major markets (France, Germany, Japan, the UK and the US).

* Includes a five-year forecast of the industry

Highlights The global pharmaceuticals market grew by 3.5% in 2011 to reach a value of $782.1 billion.

In 2016, the global pharmaceuticals market is forecast to have a value of $971.1 billion, an increase of 24.2% since 2011.

Americas accounts for 42.2% of the global pharmaceuticals market value.

Pfizer is the leading player in the global pharmaceuticals market, generating a 8.7% share of the market's value.

Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.

TABLE OF CONTENTSEXECUTIVE SUMMARY 2Market value 2Market value forecast 2Geography segmentation 2Market share 2Introduction 19What is this report about? 19Who is the target reader? 19How to use this report 19Definitions 19Global Pharmaceuticals 20Market Overview 20Market Data 21Market Segmentation 22Market outlook 24Five forces analysis 25Pharmaceuticals in Asia-Pacific 33Market Overview 33Market Data 34Market Segmentation 35Market outlook 37Five forces analysis 38Pharmaceuticals in Europe 46Market Overview 46Market Data 47Market Segmentation 48Market outlook 50Five forces analysis 51Pharmaceuticals in France 59Market Overview 59Market Data 60Market Segmentation 61Market outlook 63Five forces analysis 64Macroeconomic indicators 72Pharmaceuticals in Germany 74Market Overview 74Market Data 75Market Segmentation 76Market outlook 78Five forces analysis 79Macroeconomic indicators 87Pharmaceuticals in Italy 89Market Overview 89Market Data 90Market Segmentation 91Market outlook 93Five forces analysis 94Macroeconomic indicators 102Pharmaceuticals in Japan 104Market Overview 104Market Data 105Market Segmentation 106Market outlook 108Five forces analysis 109Macroeconomic indicators 117Pharmaceuticals in Belgium 119Market Overview 119Market Data 120Market Segmentation 121Market outlook 123Five forces analysis 124Macroeconomic indicators 132Pharmaceuticals in Canada 134Market Overview 134Market Data 135Market Segmentation 136Market outlook 138Five forces analysis 139Macroeconomic indicators 147Pharmaceuticals in China 149Market Overview 149Market Data 150Market Segmentation 151Market outlook 153Five forces analysis 154Macroeconomic indicators 162Pharmaceuticals in The Netherlands 164Market Overview 164Market Data 165Market Segmentation 166Market outlook 168Five forces analysis 169Macroeconomic indicators 177Pharmaceuticals in Spain 179Market Overview 179Market Data 180Market Segmentation 181Market outlook 183Five forces analysis 184Macroeconomic indicators 192Pharmaceuticals in The United Kingdom 194Market Overview 194Market Data 195Market Segmentation 196Market outlook 198Five forces analysis 199Macroeconomic indicators 207Pharmaceuticals in The United States 209Market Overview 209Market Data 210Market Segmentation 211Market outlook 213Five forces analysis 214Macroeconomic indicators 222Company Profiles 224Leading companies 224Appendix 267Methodology 267

LIST OF TABLES

Table 1: Global pharmaceuticals market value: $ billion, 2007–11 21

Table 2: Global pharmaceuticals market geography segmentation: $ billion, 2011 22

Table 3: Global pharmaceuticals market share: % share, by value, 2011 23

Table 4: Global pharmaceuticals market value forecast: $ billion, 2011–16 24

Table 5: Asia-Pacific pharmaceuticals market value: $ billion, 2007–11 34

Table 6: Asia–Pacific pharmaceuticals market geography segmentation: $ billion, 2011 35

Table 7: Asia-Pacific pharmaceuticals market share: % share, by value, 2011 36

Table 8: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2011–16 37

Table 9: Europe pharmaceuticals market value: $ billion, 2007–11 47

Table 10: Europe pharmaceuticals market geography segmentation: $ billion, 2011 48

Table 11: Europe pharmaceuticals market share: % share, by value, 2011 49

Table 12: Europe pharmaceuticals market value forecast: $ billion, 2011–16 50

Table 13: France pharmaceuticals market value: $ billion, 2007–11 60

Table 14: France pharmaceuticals market geography segmentation: $ billion, 2011 61

Table 15: France pharmaceuticals market share: % share, by value, 2011 62

Table 16: France pharmaceuticals market value forecast: $ billion, 2011–16 63

Table 17: France size of population (million), 2007–11 72

Table 18: France gdp (constant 2000 prices, $ billion), 2007–11 72

Table 19: France gdp (current prices, $ billion), 2007–11 72

Table 20: France inflation, 2007–11 73

Table 21: France consumer price index (absolute), 2007–11 73

Table 22: France exchange rate, 2007–11 73

Table 23: Germany pharmaceuticals market value: $ billion, 2007–11 75

Table 24: Germany pharmaceuticals market geography segmentation: $ billion, 2011 76

Table 25: Germany pharmaceuticals market share: % share, by value, 2011 77

Table 26: Germany pharmaceuticals market value forecast: $ billion, 2011–16 78

Table 27: Germany size of population (million), 2007–11 87

Table 28: Germany gdp (constant 2000 prices, $ billion), 2007–11 87

Table 29: Germany gdp (current prices, $ billion), 2007–11 87

Table 30: Germany inflation, 2007–11 88

Table 31: Germany consumer price index (absolute), 2007–11 88

Table 32: Germany exchange rate, 2007–11 88

Table 33: Italy pharmaceuticals market value: $ billion, 2007–11 90

Table 34: Italy pharmaceuticals market geography segmentation: $ billion, 2011 91

Table 35: Italy pharmaceuticals market share: % share, by value, 2011 92

Table 36: Italy pharmaceuticals market value forecast: $ billion, 2011–16 93

Table 37: Italy size of population (million), 2007–11 102

Table 38: Italy gdp (constant 2000 prices, $ billion), 2007–11 102

Table 39: Italy gdp (current prices, $ billion), 2007–11 102

Table 40: Italy inflation, 2007–11 103

Table 41: Italy consumer price index (absolute), 2007–11 103

Table 42: Italy exchange rate, 2007–11 103

Table 43: Japan pharmaceuticals market value: $ billion, 2007–11 105

Table 44: Japan pharmaceuticals market geography segmentation: $ billion, 2011 106

Table 45: Japan pharmaceuticals market share: % share, by value, 2011 107

Table 46: Japan pharmaceuticals market value forecast: $ billion, 2011–16 108

Table 47: Japan size of population (million), 2007–11 117

Table 48: Japan gdp (constant 2000 prices, $ billion), 2007–11 117

Table 49: Japan gdp (current prices, $ billion), 2007–11 117

Table 50: Japan inflation, 2007–11 118

Table 51: Japan consumer price index (absolute), 2007–11 118

Table 52: Japan exchange rate, 2007–11 118

Table 53: Belgium pharmaceuticals market value: $ billion, 2007–11 120

Table 54: Belgium pharmaceuticals market geography segmentation: $ billion, 2011 121

Table 55: Belgium pharmaceuticals market share: % share, by value, 2011 122

Table 56: Belgium pharmaceuticals market value forecast: $ billion, 2011–16 123

Table 57: Belgium size of population (million), 2007–11 132

Table 58: Belgium gdp (constant 2000 prices, $ billion), 2007–11 132

Table 59: Belgium gdp (current prices, $ billion), 2007–11 132

Table 60: Belgium inflation, 2007–11 133

Table 61: Belgium consumer price index (absolute), 2007–11 133

Table 62: Belgium exchange rate, 2007–11 133

Table 63: Canada pharmaceuticals market value: $ billion, 2007–11 135

Table 64: Canada pharmaceuticals market geography segmentation: $ billion, 2011 136

Table 65: Canada pharmaceuticals market share: % share, by value, 2011 137

Table 66: Canada pharmaceuticals market value forecast: $ billion, 2011–16 138

Table 67: Canada size of population (million), 2007–11 147

Table 68: Canada gdp (constant 2000 prices, $ billion), 2007–11 147

Table 69: Canada gdp (current prices, $ billion), 2007–11 147

Table 70: Canada inflation, 2007–11 148

Table 71: Canada consumer price index (absolute), 2007–11 148

Table 72: Canada exchange rate, 2007–11 148

Table 73: China pharmaceuticals market value: $ billion, 2007–11 150

Table 74: China pharmaceuticals market geography segmentation: $ billion, 2011 151

Table 75: China pharmaceuticals market share: % share, by value, 2011 152

Table 76: China pharmaceuticals market value forecast: $ billion, 2011–16 153

Table 77: China size of population (million), 2007–11 162

Table 78: China gdp (constant 2000 prices, $ billion), 2007–11 162

Table 79: China gdp (current prices, $ billion), 2007–11 162

Table 80: China inflation, 2007–11 163

Table 81: China consumer price index (absolute), 2007–11 163

Table 82: China exchange rate, 2007–11 163

Table 83: Netherlands pharmaceuticals market value: $ million, 2007–11 165

Table 84: Netherlands pharmaceuticals market geography segmentation: $ million, 2011 166

Table 85: Netherlands pharmaceuticals market share: % share, by value, 2011 167

Table 86: Netherlands pharmaceuticals market value forecast: $ million, 2011–16 168

Table 87: Netherlands size of population (million), 2007–11 177

Table 88: Netherlands gdp (constant 2000 prices, $ billion), 2007–11 177

Table 89: Netherlands gdp (current prices, $ billion), 2007–11 177

Table 90: Netherlands inflation, 2007–11 178

Table 91: Netherlands consumer price index (absolute), 2007–11 178

Table 92: Netherlands exchange rate, 2007–11 178

Table 93: Spain pharmaceuticals market value: $ billion, 2007–11 180

Table 94: Spain pharmaceuticals market geography segmentation: $ billion, 2011 181

Table 95: Spain pharmaceuticals market share: % share, by value, 2011 182

Table 96: Spain pharmaceuticals market value forecast: $ billion, 2011–16 183

Table 97: Spain size of population (million), 2007–11 192

Table 98: Spain gdp (constant 2000 prices, $ billion), 2007–11 192

Table 99: Spain gdp (current prices, $ billion), 2007–11 192

Table 100: Spain inflation, 2007–11 193

Table 101: Spain consumer price index (absolute), 2007–11 193

Table 102: Spain exchange rate, 2007–11 193

Table 103: United Kingdom pharmaceuticals market value: $ billion, 2007–11 195

Table 104: United Kingdom pharmaceuticals market geography segmentation: $ billion, 2011 196

Table 105: United Kingdom pharmaceuticals market share: % share, by value, 2011 197

Table 106: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 198

Table 107: United Kingdom size of population (million), 2007–11 207

Table 108: United Kingdom gdp (constant 2000 prices, $ billion), 2007–11 207

Table 109: United Kingdom gdp (current prices, $ billion), 2007–11 207

Table 110: United Kingdom inflation, 2007–11 208

Table 111: United Kingdom consumer price index (absolute), 2007–11 208

Table 112: United Kingdom exchange rate, 2007–11 208

Table 113: United States pharmaceuticals market value: $ billion, 2007–11 210

Table 114: United States pharmaceuticals market geography segmentation: $ billion, 2011 211

Table 115: United States pharmaceuticals market share: % share, by value, 2011 212

Table 116: United States pharmaceuticals market value forecast: $ billion, 2011–16 213

Table 117: United States size of population (million), 2007–11 222

Table 118: United States gdp (constant 2000 prices, $ billion), 2007–11 222

Table 119: United States gdp (current prices, $ billion), 2007–11 222

Table 120: United States inflation, 2007–11 223

Table 121: United States consumer price index (absolute), 2007–11 223

Table 122: United States exchange rate, 2007–11 223

Table 123: Pfizer Inc.: key facts 224

Table 124: Pfizer Inc.: key financials ($) 225

Table 125: Pfizer Inc.: key financial ratios 225

Table 126: GlaxoSmithKline Plc: key facts 227

Table 127: GlaxoSmithKline Plc: key financials ($) 228

Table 128: GlaxoSmithKline Plc: key financials (£) 229

Table 129: GlaxoSmithKline Plc: key financial ratios 229

Table 130: AstraZeneca PLC: key facts 231

Table 131: AstraZeneca PLC: key financials ($) 232

Table 132: AstraZeneca PLC: key financial ratios 233

Table 133: Merck & Co., Inc.: key facts 235

Table 134: Merck & Co., Inc.: key financials ($) 236

Table 135: Merck & Co., Inc.: key financial ratios 236

Table 136: Daiichi Sankyo Co., Ltd.: key facts 238

Table 137: Daiichi Sankyo Co., Ltd.: key financials ($) 239

Table 138: Daiichi Sankyo Co., Ltd.: key financials (¥) 239

Table 139: Daiichi Sankyo Co., Ltd.: key financial ratios 239

Table 140: Astellas Pharma Inc.: key facts 241

Table 141: Astellas Pharma Inc.: key financials ($) 242

Table 142: Astellas Pharma Inc.: key financials (¥) 242

Table 143: Astellas Pharma Inc.: key financial ratios 242

Table 144: Novartis AG: key facts 244

Table 145: Novartis AG: key financials ($) 245

Table 146: Novartis AG: key financial ratios 245

Table 147: Chiesi Farmaceutici S.P.A.: key facts 247

Table 148: Menarini Group, The: key facts 249

Table 149: Takeda Pharmaceutical Company Limited: key facts 250

Table 150: Takeda Pharmaceutical Company Limited: key financials ($) 251

Table 151: Takeda Pharmaceutical Company Limited: key financials (¥) 251

Table 152: Takeda Pharmaceutical Company Limited: key financial ratios 251

Table 153: Mitsubishi Tanabe Pharma Corporation: key facts 253

Table 154: Mitsubishi Tanabe Pharma Corporation: key financials ($) 254

Table 155: Mitsubishi Tanabe Pharma Corporation: key financials (¥) 254

Table 156: Mitsubishi Tanabe Pharma Corporation: key financial ratios 254

Table 157: Johnson & Johnson: key facts 256

Table 158: Johnson & Johnson: key financials ($) 257

Table 159: Johnson & Johnson: key financial ratios 257

Table 160: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 259

Table 161: Almirall S.A.: key facts 260

Table 162: Almirall S.A.: key financials ($) 260

Table 163: Almirall S.A.: key financials (€) 261

Table 164: Almirall S.A.: key financial ratios 261

Table 165: Sanofi: key facts 263

Table 166: Sanofi: key financials ($) 264

Table 167: Sanofi: key financials (€) 264

Table 168: Sanofi: key financial ratios 265

LIST OF FIGURESFigure 1: Global pharmaceuticals market value: $ billion, 2007–11 25Figure 2: Global pharmaceuticals market geography segmentation: % share, by value, 2011 26Figure 3: Global pharmaceuticals market share: % share, by value, 2011 27Figure 4: Global pharmaceuticals market value forecast: $ billion, 2011–16 28Figure 5: Forces driving competition in the global pharmaceuticals market, 2011 29Figure 6: Drivers of buyer power in the global pharmaceuticals market, 2011 30Figure 7: Drivers of supplier power in the global pharmaceuticals market, 2011 32Figure 8: Factors influencing the likelihood of new entrants in the global pharmaceuticals market, 2011 33Figure 9: Factors influencing the threat of substitutes in the global pharmaceuticals market, 2011 35Figure 10: Drivers of degree of rivalry in the global pharmaceuticals market, 2011 36Figure 11: Asia-Pacific pharmaceuticals market value: $ billion, 2007–11 38Figure 12: Asia–Pacific pharmaceuticals market geography segmentation: % share, by value, 2011 39Figure 13: Asia-Pacific pharmaceuticals market share: % share, by value, 2011 40Figure 14: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2011–16 41Figure 15: Forces driving competition in the pharmaceuticals market in Asia-Pacific, 2011 42Figure 16: Drivers of buyer power in the pharmaceuticals market in Asia-Pacific, 2011 43Figure 17: Drivers of supplier power in the pharmaceuticals market in Asia-Pacific, 2011 45Figure 18: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Asia-Pacific, 2011 46Figure 19: Factors influencing the threat of substitutes in the pharmaceuticals market in Asia-Pacific, 2011 48Figure 20: Drivers of degree of rivalry in the pharmaceuticals market in Asia-Pacific, 2011 49Figure 21: Europe pharmaceuticals market value: $ billion, 2007–11 51Figure 22: Europe pharmaceuticals market geography segmentation: % share, by value, 2011 52Figure 23: Europe pharmaceuticals market share: % share, by value, 2011 53Figure 24: Europe pharmaceuticals market value forecast: $ billion, 2011–16 54Figure 25: Forces driving competition in the pharmaceuticals market in Europe, 2011 55Figure 26: Drivers of buyer power in the pharmaceuticals market in Europe, 2011 56Figure 27: Drivers of supplier power in the pharmaceuticals market in Europe, 2011 58Figure 28: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Europe, 2011 59Figure 29: Factors influencing the threat of substitutes in the pharmaceuticals market in Europe, 2011 61Figure 30: Drivers of degree of rivalry in the pharmaceuticals market in Europe, 2011 62Figure 31: France pharmaceuticals market value: $ billion, 2007–11 64Figure 32: France pharmaceuticals market geography segmentation: % share, by value, 2011 65Figure 33: France pharmaceuticals market share: % share, by value, 2011 66Figure 34: France pharmaceuticals market value forecast: $ billion, 2011–16 67Figure 35: Forces driving competition in the pharmaceuticals market in France, 2011 68Figure 36: Drivers of buyer power in the pharmaceuticals market in France, 2011 69Figure 37: Drivers of supplier power in the pharmaceuticals market in France, 2011 71Figure 38: Factors influencing the likelihood of new entrants in the pharmaceuticals market in France, 2011 72Figure 39: Factors influencing the threat of substitutes in the pharmaceuticals market in France, 2011 74Figure 40: Drivers of degree of rivalry in the pharmaceuticals market in France, 2011 75Figure 41: Germany pharmaceuticals market value: $ billion, 2007–11 79Figure 42: Germany pharmaceuticals market geography segmentation: % share, by value, 2011 80Figure 43: Germany pharmaceuticals market share: % share, by value, 2011 81Figure 44: Germany pharmaceuticals market value forecast: $ billion, 2011–16 82Figure 45: Forces driving competition in the pharmaceuticals market in Germany, 2011 83Figure 46: Drivers of buyer power in the pharmaceuticals market in Germany, 2011 84Figure 47: Drivers of supplier power in the pharmaceuticals market in Germany, 2011 86Figure 48: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Germany, 2011 87Figure 49: Factors influencing the threat of substitutes in the pharmaceuticals market in Germany, 2011 89Figure 50: Drivers of degree of rivalry in the pharmaceuticals market in Germany, 2011 90Figure 51: Italy pharmaceuticals market value: $ billion, 2007–11 94Figure 52: Italy pharmaceuticals market geography segmentation: % share, by value, 2011 95Figure 53: Italy pharmaceuticals market share: % share, by value, 2011 96Figure 54: Italy pharmaceuticals market value forecast: $ billion, 2011–16 97Figure 55: Forces driving competition in the pharmaceuticals market in Italy, 2011 98Figure 56: Drivers of buyer power in the pharmaceuticals market in Italy, 2011 99Figure 57: Drivers of supplier power in the pharmaceuticals market in Italy, 2011 101Figure 58: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Italy, 2011 102Figure 59: Factors influencing the threat of substitutes in the pharmaceuticals market in Italy, 2011 104Figure 60: Drivers of degree of rivalry in the pharmaceuticals market in Italy, 2011 105Figure 61: Japan pharmaceuticals market value: $ billion, 2007–11 109Figure 62: Japan pharmaceuticals market geography segmentation: % share, by value, 2011 110Figure 63: Japan pharmaceuticals market share: % share, by value, 2011 111Figure 64: Japan pharmaceuticals market value forecast: $ billion, 2011–16 112Figure 65: Forces driving competition in the pharmaceuticals market in Japan, 2011 113Figure 66: Drivers of buyer power in the pharmaceuticals market in Japan, 2011 114Figure 67: Drivers of supplier power in the pharmaceuticals market in Japan, 2011 116Figure 68: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Japan, 2011 117Figure 69: Factors influencing the threat of substitutes in the pharmaceuticals market in Japan, 2011 119Figure 70: Drivers of degree of rivalry in the pharmaceuticals market in Japan, 2011 120Figure 71: Belgium pharmaceuticals market value: $ billion, 2007–11 124Figure 72: Belgium pharmaceuticals market geography segmentation: % share, by value, 2011 125Figure 73: Belgium pharmaceuticals market share: % share, by value, 2011 126Figure 74: Belgium pharmaceuticals market value forecast: $ billion, 2011–16 127Figure 75: Forces driving competition in the pharmaceuticals market in Belgium, 2011 128Figure 76: Drivers of buyer power in the pharmaceuticals market in Belgium, 2011 129Figure 77: Drivers of supplier power in the pharmaceuticals market in Belgium, 2011 131Figure 78: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Belgium, 2011 132Figure 79: Factors influencing the threat of substitutes in the pharmaceuticals market in Belgium, 2011 134Figure 80: Drivers of degree of rivalry in the pharmaceuticals market in Belgium, 2011 135Figure 81: Canada pharmaceuticals market value: $ billion, 2007–11 139Figure 82: Canada pharmaceuticals market geography segmentation: % share, by value, 2011 140Figure 83: Canada pharmaceuticals market share: % share, by value, 2011 141Figure 84: Canada pharmaceuticals market value forecast: $ billion, 2011–16 142Figure 85: Forces driving competition in the pharmaceuticals market in Canada, 2011 143Figure 86: Drivers of buyer power in the pharmaceuticals market in Canada, 2011 144Figure 87: Drivers of supplier power in the pharmaceuticals market in Canada, 2011 146Figure 88: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Canada, 2011 147Figure 89: Factors influencing the threat of substitutes in the pharmaceuticals market in Canada, 2011 149Figure 90: Drivers of degree of rivalry in the pharmaceuticals market in Canada, 2011 150Figure 91: China pharmaceuticals market value: $ billion, 2007–11 154Figure 92: China pharmaceuticals market geography segmentation: % share, by value, 2011 155Figure 93: China pharmaceuticals market share: % share, by value, 2011 156Figure 94: China pharmaceuticals market value forecast: $ billion, 2011–16 157Figure 95: Forces driving competition in the pharmaceuticals market in China, 2011 158Figure 96: Drivers of buyer power in the pharmaceuticals market in China, 2011 159Figure 97: Drivers of supplier power in the pharmaceuticals market in China, 2011 161Figure 98: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2011 162Figure 99: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2011 164Figure 100: Drivers of degree of rivalry in the pharmaceuticals market in China, 2011 165Figure 101: Netherlands pharmaceuticals market value: $ million, 2007–11 169Figure 102: Netherlands pharmaceuticals market geography segmentation: % share, by value, 2011 170Figure 103: Netherlands pharmaceuticals market share: % share, by value, 2011 171Figure 104: Netherlands pharmaceuticals market value forecast: $ million, 2011–16 172Figure 105: Forces driving competition in the pharmaceuticals market in the Netherlands, 2011 173Figure 106: Drivers of buyer power in the pharmaceuticals market in the Netherlands, 2011 174Figure 107: Drivers of supplier power in the pharmaceuticals market in the Netherlands, 2011 176Figure 108: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the Netherlands, 2011 177Figure 109: Factors influencing the threat of substitutes in the pharmaceuticals market in the Netherlands, 2011 179Figure 110: Drivers of degree of rivalry in the pharmaceuticals market in the Netherlands, 2011 180Figure 111: Spain pharmaceuticals market value: $ billion, 2007–11 184Figure 112: Spain pharmaceuticals market geography segmentation: % share, by value, 2011 185Figure 113: Spain pharmaceuticals market share: % share, by value, 2011 186Figure 114: Spain pharmaceuticals market value forecast: $ billion, 2011–16 187Figure 115: Forces driving competition in the pharmaceuticals market in Spain, 2011 188Figure 116: Drivers of buyer power in the pharmaceuticals market in Spain, 2011 189Figure 117: Drivers of supplier power in the pharmaceuticals market in Spain, 2011 191Figure 118: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Spain, 2011 192Figure 119: Factors influencing the threat of substitutes in the pharmaceuticals market in Spain, 2011 194Figure 120: Drivers of degree of rivalry in the pharmaceuticals market in Spain, 2011 195Figure 121: United Kingdom pharmaceuticals market value: $ billion, 2007–11 199Figure 122: United Kingdom pharmaceuticals market geography segmentation: % share, by value, 2011 200Figure 123: United Kingdom pharmaceuticals market share: % share, by value, 2011 201Figure 124: United Kingdom pharmaceuticals market value forecast: $ billion, 2011–16 202Figure 125: Forces driving competition in the pharmaceuticals market in the United Kingdom, 2011 203Figure 126: Drivers of buyer power in the pharmaceuticals market in the United Kingdom, 2011 204Figure 127: Drivers of supplier power in the pharmaceuticals market in the United Kingdom, 2011 206Figure 128: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United Kingdom, 2011 207Figure 129: Factors influencing the threat of substitutes in the pharmaceuticals market in the United Kingdom, 2011 209Figure 130: Drivers of degree of rivalry in the pharmaceuticals market in the United Kingdom, 2011 210Figure 131: United States pharmaceuticals market value: $ billion, 2007–11 214Figure 132: United States pharmaceuticals market geography segmentation: % share, by value, 2011 215Figure 133: United States pharmaceuticals market share: % share, by value, 2011 216Figure 134: United States pharmaceuticals market value forecast: $ billion, 2011–16 217Figure 135: Forces driving competition in the pharmaceuticals market in the United States, 2011 218Figure 136: Drivers of buyer power in the pharmaceuticals market in the United States, 2011 219Figure 137: Drivers of supplier power in the pharmaceuticals market in the United States, 2011 221Figure 138: Factors influencing the likelihood of new entrants in the pharmaceuticals market in the United States, 2011 222Figure 139: Factors influencing the threat of substitutes in the pharmaceuticals market in the United States, 2011 224Figure 140: Drivers of degree of rivalry in the pharmaceuticals market in the United States, 2011 225Figure 141: Pfizer Inc.: revenues & profitability 230Figure 142: Pfizer Inc.: assets & liabilities 230Figure 143: GlaxoSmithKline Plc: revenues & profitability 233Figure 144: GlaxoSmithKline Plc: assets & liabilities 234Figure 145: AstraZeneca PLC: revenues & profitability 237Figure 146: AstraZeneca PLC: assets & liabilities 238Figure 147: Merck & Co., Inc.: revenues & profitability 240Figure 148: Merck & Co., Inc.: assets & liabilities 241Figure 149: Daiichi Sankyo Co., Ltd.: revenues & profitability 244Figure 150: Daiichi Sankyo Co., Ltd.: assets & liabilities 244Figure 151: Astellas Pharma Inc.: revenues & profitability 247Figure 152: Astellas Pharma Inc.: assets & liabilities 247Figure 153: Novartis AG: revenues & profitability 250Figure 154: Novartis AG: assets & liabilities 250Figure 155: Takeda Pharmaceutical Company Limited: revenues & profitability 256Figure 156: Takeda Pharmaceutical Company Limited: assets & liabilities 256Figure 157: Mitsubishi Tanabe Pharma Corporation: revenues & profitability 259Figure 158: Mitsubishi Tanabe Pharma Corporation: assets & liabilities 259Figure 159: Johnson & Johnson: revenues & profitability 261Figure 160: Johnson & Johnson: assets & liabilities 262Figure 161: Almirall S.A.: revenues & profitability 265Figure 162: Almirall S.A.: assets & liabilities 266Figure 163: Sanofi: revenues & profitability 269Figure 164: Sanofi: assets & liabilities 270

To order this report:Pharmaceutical Industry: Pharmaceuticals: Global Industry Guide

Contact
Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Reliance Pharmaceuticals: Biosimilars Company Analysis
2. Pharmaceuticals: Global Industry Almanac, MarketLine
3. OTC Pharmaceuticals: Global Industry Almanac, MarketLine
4. Global Biosimilars: A return to optimism?
5. Global Bariatric (Obesity) Surgical Devices Industry
6. Global Digital Radiography Industry
7. Global Market for Industrial and Institutional Cleaning Products to Exceed $52 Billion by 2018, Hand Sanitizers Poised to Reach $226.3 Million by 2018
8. CAHG Wins Global Award for Third Consecutive Year
9. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
10. Global Market for Radiation Therapy Equipment to Reach $6.8 Billion by 2018
11. Global Market for Laboratory Glassware and Plasticware to Reach $6.16 Billion by 2018, Pipettes and Pipettors Market $1.1 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... 2016 /PRNewswire/ - Demers Ambulances announces its first delivery in the ... Okaloosa County Emergency Medical Services (EMS) consisting of ... LT2 van. Quality Emergency Vehicles in Lecanto, FL ... sale.  This is the latest in Demers, ongoing expansion of ... at Demers. --> Benoit LaFortune , Executive Vice ...
(Date:2/12/2016)... HOUSTON , Feb. 12, 2016  Memorial Hermann ... center Dwight Howard to bring a one-of-a-kind ... Hospital . Using cutting-edge technologies such as 360-degree video ... kids both virtually, then literally – giving the patients ... – and it was all caught on video ...
(Date:2/12/2016)... 2016  Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ ) ... will ring the Nasdaq Closing Bell at the Nasdaq ... at 4:00 p.m. ET on Tuesday, February 16, ... Adrian Adams , will perform the honorary bell ... p.m. ET.  A live webcast will be available at: ...
Breaking Medicine Technology:
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , Back to the ... , As Winston Churchill said, “Those who don’t learn from history are ... what to expect when they come knocking this year. But that takes time. , ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Each year, the ... be held in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists ... new therapy products in action, learn more about their chosen field and network with ...
(Date:2/12/2016)... ... 12, 2016 , ... Coco Libre, the maker of coconut water beverages with ... Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s signature Organic ... The invitation-only gifting suite, held this year at the W Hollywood Hotel, has become ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ThedaCare ... San Francisco General Hospital on April 5-7. The series is a multi-day, multi-workshop ... habits. The workshops cover a broad range of topics, including coaching skills, the ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Every winter, someone ... This winter the West Penn Burn Center, part of the Allegheny Health ... to bring you the “Space Heaters Need Space” campaign. , “Space ...
Breaking Medicine News(10 mins):